Featured Research

from universities, journals, and other organizations

Technique that removes additional toxins prolongs dialysis patients' lives

Date:
February 14, 2013
Source:
American Society of Nephrology
Summary:
A technique that removes additional toxins during dialysis decreased kidney failure patients' risk of dying from any cause by 30 percent over three years. The technique also reduced patients' risk of dying from heart-related causes or infections. 15 to 25 percent of dialysis patients die annually.

A technique that removes additional toxins during dialysis may prolong kidney failure patients' lives, according to a clinical trial appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). In light of these results, the technique may become standard for dialysis patients.

Retrospective studies suggest that on-line hemodiafiltration (OL-HDF) -- which is different from standard dialysis in that it uses so-called high convective transport to remove additional substances over a wide range of sizes -- may reduce kidney failure patients' risk of dying prematurely compared with standard hemodialysis. However, results from prospective studies have contradicted this finding.

To investigate the issue further, Francisco Maduell, MD, PhD (Hospital Clinic, in Barcelona, Spain) and his colleagues conducted a multicenter, open-label, randomized controlled trial in which they assigned 906 dialysis patients either to continue hemodialysis or to switch to OL-HDF, with higher convective volume than in previous prospective trials. Patients were followed for three years.

Among the major findings over the course of the three-year study:

  • Compared with patients who continued on hemodialysis, those assigned to OL-HDF had a 30% lower risk of dying from any cause, a 33% lower risk of dying from cardiovascular-related causes, and a 55% lower risk of dying from an infection.
  • The study's findings suggest that switching eight patients from hemodialysis to OL-HDF may prevent one annual death.
  • Hospitalizations and dialysis sessions complicated by low blood pressure were lower in patients assigned to OL-HDF.

The findings indicate that OL-HDF may indeed prolong kidney failure patients' lives compared with conventional hemodialysis. "Mortality remains very high in dialysis patients, ranging from 15% to 25% annually. Any reduction of this mortality would be an important achievement," said Dr. Maduell. "In view of this study's results, OL-HDF may become the first-line option in hemodialysis patients," he added.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. F. Maduell, F. Moreso, M. Pons, R. Ramos, J. Mora-Macia, J. Carreras, J. Soler, F. Torres, J. M. Campistol, A. Martinez-Castelao. High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology, 2013; DOI: 10.1681/ASN.2012080875

Cite This Page:

American Society of Nephrology. "Technique that removes additional toxins prolongs dialysis patients' lives." ScienceDaily. ScienceDaily, 14 February 2013. <www.sciencedaily.com/releases/2013/02/130214194053.htm>.
American Society of Nephrology. (2013, February 14). Technique that removes additional toxins prolongs dialysis patients' lives. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/02/130214194053.htm
American Society of Nephrology. "Technique that removes additional toxins prolongs dialysis patients' lives." ScienceDaily. www.sciencedaily.com/releases/2013/02/130214194053.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins